{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T03:26:59Z","timestamp":1776396419420,"version":"3.51.2"},"reference-count":14,"publisher":"Japanese Society of Internal Medicine","issue":"21","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2022,11,1]]},"DOI":"10.2169\/internalmedicine.9699-22","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T22:11:20Z","timestamp":1660947080000},"page":"3205-3210","source":"Crossref","is-referenced-by-count":7,"title":["Association of Systemic Adverse Reactions and Serum SARS-CoV-2 Spike Protein Antibody Levels after Administration of BNT162b2 mRNA COVID-19 Vaccine"],"prefix":"10.2169","volume":"61","author":[{"given":"Wataru","family":"Takahashi","sequence":"first","affiliation":[{"name":"Department of Clinical Research, National Hospital Organization, Shinshu Ueda Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiko","family":"Mizuno","sequence":"additional","affiliation":[{"name":"Department of Clinical Research, National Hospital Organization, Shinshu Ueda Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaori","family":"Hara","sequence":"additional","affiliation":[{"name":"Department of Infection Control, National Hospital Organization, Shinshu Ueda Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Ara","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, National Hospital Organization, Shinshu Ueda Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rikiya","family":"Hurutani","sequence":"additional","affiliation":[{"name":"Department of Neurology, National Hospital Organization, Shinshu Ueda Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihiko","family":"Agatsuma","sequence":"additional","affiliation":[{"name":"Department of Infection Control, National Hospital Organization, Shinshu Ueda Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minoru","family":"Fujimori","sequence":"additional","affiliation":[{"name":"Department of Breast Surgery, National Hospital Organization, Shinshu Ueda Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","unstructured":"1. Prime minister of Japan and His cabinet. Information related to COVID-19 [Internet]. Available from: https:\/\/japan.kantei.go.jp\/ongoingtopics\/vaccine.html"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Xia X. Domains and functions of spike protein in SARS-CoV-2 in the context of vaccine design. Viruses 13: 109, 2021.","DOI":"10.3390\/v13010109"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Huang Y, Chan Y, Xin-Feng X, Wei X, Shu-Wen L. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin 41: 1141-1149, 2020.","DOI":"10.1038\/s41401-020-0485-4"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Polack FP, Thomas ST, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA COVID-19 vaccine. N Engl J Med 385: 1761-1773, 2021.","DOI":"10.1056\/NEJMoa2110345"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Yamamoto S, Fukunaga A, Tanaka A, et al. Association between reactogenicity and SARS-CoV-2 antibodies after the second dose of the BNT162b2 COVID-19 vaccine. Vaccine 18: 1924-1927, 2022.","DOI":"10.1016\/j.vaccine.2022.02.052"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Mochizuki T, Hori T, Yano K, Ikari K, Okazaki K. Factors associated with change in SARS-CoV-2 antibody titers from three to six months after the administration of the BNT162b2 mRNA COVID-19 vaccine among healthcare workers in Japan: a prospective study. Intern Med 61: 1139-1143, 2022.","DOI":"10.2169\/internalmedicine.8902-21"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Oyebanji OA, Wilson B, Keresztesy D, et al. Does a lack of vaccine side effects correlate with reduced BNT162b2 mRNA vaccine response among healthcare workers and nursing home residents? Aging Clin Exp Res 33: 3151-3160, 2021.","DOI":"10.1007\/s40520-021-01987-9"},{"key":"8","unstructured":"8. Florian K, Srivastava K, Alshammary H, et al. Antibody responses in seropositive persons after a single dose of SARS-CoV-2 mRNA vaccine. N Engl J Med 384: 1372-1374, 2021."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Hwang YH, Song KH, Choi Y, et al. Can reactogenicity predict immunogenicity after COVID-19 vaccination? Korean J Intern Med 36: 1486-1491, 2021.","DOI":"10.3904\/kjim.2021.210"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Yaniv L, Sapir E, Regev-Yochay G, et al. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers. Lancet Respir Med 9: 999-1009, 2021.","DOI":"10.1016\/S2213-2600(21)00220-4"},{"key":"11","doi-asserted-by":"publisher","unstructured":"11. Giacomo G, Zangrillo A, Zanella A, et al.; COVID-19 Lombardy ICU Network. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA 323: 1574-1581, 2020.","DOI":"10.1001\/jama.2020.5394"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Kageyama T, Ikeda K, Tanaka S, et al. Antibody responses to BNT162b2 mRNA COVID-19 vaccine and their predictors among healthcare workers in a tertiary referral hospital in Japan. Clin Microbiol Infect 27: 1861.e1-1861.e5, 2021.","DOI":"10.1016\/j.cmi.2021.07.042"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Thomas SJ, Moreira ED, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months. N Engl J Med 385: 1761-1773, 2021.","DOI":"10.1056\/NEJMoa2110345"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Montoya JG, Amy EA, Val\u00e9rie B, et al. Differences in IgG antibody responses following BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines. Microbiol Spectr 9: e0116221, 2021.","DOI":"10.1128\/Spectrum.01162-21"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/21\/61_9699-22\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,5]],"date-time":"2022-11-05T03:23:50Z","timestamp":1667618630000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/61\/21\/61_9699-22\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":14,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.9699-22","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,1]]},"article-number":"9699-22"}}